Adaptive Biotechnologies (NASDAQ:ADPT) Chief Commercial Officer Sharon Benzeno completed a sale of 63,103 shares of the company’s common stock on March 11, 2026. The shares changed hands at $13.17 apiece, producing a transaction amount of $831,066, according to a Form 4 filing with the Securities and Exchange Commission.
The filing specifies the sale was carried out to fund tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). Adaptive Biotechnologies’ equity incentive plans require that such tax obligations be satisfied through a "sell to cover" mechanism, and the Form 4 shows the transaction was consistent with that mandate. Following the disposition, Benzeno is reported to directly own 272,751 shares.
The share sale comes against a backdrop of recent price movement for the stock. Shares fell 11% over the past week, even as the company’s one-year performance remains substantially higher, with the stock up 81% over the prior 12 months.
Adaptive Biotechnologies, with a market capitalization reported at $2.01 billion, is currently trading above a reported fair value estimate, a dynamic that has been noted as potentially indicating the stock may be overvalued at its present levels.
Separately, Adaptive Biotechnologies released fourth-quarter 2025 results that outperformed expectations. The company posted an earnings per share (EPS) of -$0.09, beating the analyst consensus of -$0.18 and representing a 50% positive surprise versus estimates. Quarterly revenue totaled $71.7 million, ahead of the $59.33 million analysts had forecast, a beat of 20.85%.
Following the announced results and related guidance, several brokerages adjusted their views. BTIG raised its price target to $22.00, citing robust expansion in the company’s Minimal Residual Disease (MRD) business, which grew 54% year-over-year in Q4 and 46% for the full year. TD Cowen moved its price target to $21.00 after the company’s pre-announcement of fourth-quarter results and guidance. Piper Sandler reiterated an Overweight rating and highlighted expectations for clonoSEQ volume to increase by more than 30%.
Summary: Adaptive Biotechnologies’ chief commercial officer sold 63,103 shares on March 11, 2026, in a transaction valued at $831,066 to cover RSU-related tax withholdings required under the company’s equity plans. The sale occurred amid a recent one-week 11% decline in the stock but follows a fiscal quarter that outperformed estimates and prompted analyst target adjustments.